Kaliumchlorid Fresenius (Potassium Chloride)

Kaliumchlorid Fresenius is used in electrolyte management to treat conditions associated with low potassium levels.

• Hypokalemia: restores serum potassium concentrations to normal ranges.
• Potassium replacement therapy: supplies potassium ions for patients undergoing depletion due to diuretics or gastrointestinal losses.
• Cardiac arrhythmia prevention: helps maintain cardiac electrical stability by correcting potassium deficits.

• After intravenous administration, potassium chloride dissociates, releasing potassium ions that enter the extracellular fluid. The rise in extracellular potassium shifts the intracellular‑extracellular equilibrium, increasing serum potassium levels and re‑establishing the normal electrochemical gradient essential for nerve impulse transmission, muscle contraction, and cardiac electrophysiology.

Intravenous potassium chloride may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Pain or irritation at the injection site
• Mild hyperkalemia (transient elevation of serum potassium)
• Nausea
• Vomiting
• Tingling or paresthesia

Serious or Rare Side Effects

• Severe hyperkalemia leading to cardiac arrhythmias
• Cardiac arrest
• Anaphylactic or severe allergic reaction
• Thrombophlebitis at the infusion site
• Metabolic acidosis (rare)

When using Kaliumchlorid Fresenius, several precautions should be observed to ensure patient safety.

• Renal impairment: monitor serum potassium and renal function closely.
• Cardiac disease: obtain baseline ECG and observe for arrhythmias during infusion.
• Concomitant potassium‑sparing agents: avoid excessive potassium accumulation.
• Rapid infusion rates: administer slowly to reduce risk of venous irritation.
• Pregnancy and lactation: use only if clearly needed, as safety data are limited.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potassium chloride can interact with several medicines, affecting potassium balance or cardiac function.

Major Interactions (Avoid)

• ACE inhibitors or ARBs: may cause dangerous hyperkalemia.
• Potassium‑sparing diuretics (e.g., spironolactone): increase risk of severe hyperkalemia.
• NSAIDs: can reduce renal potassium excretion, raising serum levels.
• Trimethoprim‑sulfamethoxazole: potentiates hyperkalemia.
• Heparin therapy: may impair renal potassium handling.

Moderate Interactions (Monitor Closely)

• Digoxin: elevated potassium can enhance digoxin toxicity.
• Beta‑blockers: may mask symptoms of hyperkalemia.
• Insulin or glucose therapy: can cause rapid shifts in potassium.
• Beta‑agonists (e.g., albuterol): may lower serum potassium.
• Certain antibiotics (e.g., penicillamine): affect potassium excretion.